Home » Novavax Partners With AGC Biologics to Manufacture COVID-19 Vaccine Component
Novavax Partners With AGC Biologics to Manufacture COVID-19 Vaccine Component
Novavax has partnered with AGC Biologics of Denmark to manufacture an adjuvant for its COVID-19 vaccine candidate NVX-CoV2373.
The adjuvant enhances the immune response to the vaccine and stimulates high levels of neutralizing antibodies to the virus. AGC Biologics will scale up production of the Matrix-M adjuvant to increase Novavax’s capacity to deliver vaccine doses this year.
The Maryland-based company has begun a phase 1/2 trial of NVX‑CoV2373 in Australia and expects to release phase 1 results in July.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct